Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.65 |
| ▸ | ELOC | Q15369 | 6/20 | 0.48 |
| ▸ | ELOB | Q15370 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122545 | 0.91 | VHL (0.68) | VHLELOCELOB | |
| SCHEMBL25769006 | 0.91 | VHL (0.77) | VHLELOCELOB | |
| SCHEMBL25769070 | 0.91 | VHL (0.77) | VHLELOCELOB | |
| SCHEMBL22526032 | 0.91 | VHL (0.78) | VHLELOCELOB | |
| SCHEMBL24514322 | 0.91 | VHL (0.78) | VHLELOCELOB | |
| SCHEMBL22525883 | 0.88 | VHL (0.84) | VHLELOCELOB | |
| SCHEMBL25773041 | 0.85 | VHL (0.70) | VHLELOCELOB | |
| SCHEMBL22151430 | 0.83 | VHL (0.67) | VHLELOCELOB | |
| SCHEMBL21456038 | 0.82 | VHL (0.66) | VHLELOCELOB | |
| SCHEMBL21401582 | 0.82 | VHL (0.64) | VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | VHL 735/4885ELOC 1726/4885ELOB 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.